Trazodone Laboratory Monitoring
No routine laboratory monitoring is required when initiating or maintaining trazodone therapy for depression or insomnia. The FDA-approved prescribing information for trazodone does not mandate any baseline or ongoing laboratory tests 1.
Baseline Assessment
Before starting trazodone, no specific laboratory tests are required according to the FDA label 1. However, clinical judgment should guide assessment of:
- Cardiovascular risk factors - particularly in patients with known cardiac disease or elderly patients, as trazodone can cause orthostatic hypotension and QT prolongation 2
- Screening for bipolar disorder - obtain personal and family psychiatric history before initiating any antidepressant to assess risk of treatment-emergent mania 1
Ongoing Monitoring
No scheduled laboratory monitoring is recommended during trazodone treatment 1. The medication does not require:
- Liver function test monitoring (unlike many other psychotropic medications that require regular hepatic panels) 1
- Renal function monitoring 1
- Complete blood count monitoring 1
- Therapeutic drug level monitoring 3
Laboratory Findings Associated with Trazodone
While routine monitoring is not required, clinicians should be aware of potential laboratory changes:
- Pseudoanemia - trazodone can cause decreases in hematocrit, hemoglobin, and red blood cell count in approximately 36% of patients, though this is not considered clinically significant 4
- Decreased serum cholesterol, calcium, and albumin - these changes have been documented but are typically not clinically relevant 4
- False-positive amphetamine screens - the trazodone metabolite meta-chlorophenylpiperazine (m-CPP) can cause false-positive results on urine amphetamine immunoassays, which laboratories should recognize when interpreting drug screens 5
Clinical Monitoring Priorities
Instead of laboratory tests, focus on clinical monitoring 1, 2:
- Orthostatic vital signs - particularly during dose titration and in elderly or cardiovascular patients 2
- Emergence of suicidal ideation - especially in young adults during initial treatment 1
- Sedation and drowsiness - the most common adverse effects, which may require dose adjustment or timing changes 2
- Priapism symptoms - rare but serious adverse effect requiring immediate discontinuation 2
Important Caveats
Trazodone differs markedly from other psychotropic medications that require extensive laboratory monitoring (such as lithium, valproate, carbamazepine, or clozapine) 3. This absence of monitoring requirements makes trazodone administratively simpler but does not diminish the need for careful clinical assessment of tolerability and efficacy 1, 2.